BR112014007405A2 - composto; forma farmacêutica; e hexasulfato de inositol - Google Patents

composto; forma farmacêutica; e hexasulfato de inositol

Info

Publication number
BR112014007405A2
BR112014007405A2 BR112014007405A BR112014007405A BR112014007405A2 BR 112014007405 A2 BR112014007405 A2 BR 112014007405A2 BR 112014007405 A BR112014007405 A BR 112014007405A BR 112014007405 A BR112014007405 A BR 112014007405A BR 112014007405 A2 BR112014007405 A2 BR 112014007405A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical form
opso22
opo32
oso3
Prior art date
Application number
BR112014007405A
Other languages
English (en)
Other versions
BR112014007405B1 (pt
Inventor
Pratsinis Anna
Castagner Bastien
Schneider Gisbert
Leroux Jean-Christophe
Ivarsson Mattias
Original Assignee
Eth Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47022623&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014007405(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eth Zuerich filed Critical Eth Zuerich
Publication of BR112014007405A2 publication Critical patent/BR112014007405A2/pt
Publication of BR112014007405B1 publication Critical patent/BR112014007405B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00—Esters of sulfuric acids
    • C07C305/20—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/093—Polyol derivatives esterified at least twice by phosphoric acid groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo composto; forma farmacêutica; e hexasulfato de inositol a invenção se refere a um composto representado pela fórmula geral (1), em que cada x independentemente pode ser opo32-, opso22- ou oso3-; r1 compreende uma função de solubilidade tais como uma fração de polietilenoglicol e cada x independentemente pode ser opo32-, opso22-, ou oso3-; e z é uma cadeia de alquila compreendendo 1 a 3 carbonos e/ou heteroátomos. a invenção se refere ainda aos derivados de polissulfato ou derivados de polifosfato/sulfato mistos de polióis cíclicos com seis membros para uso na terapia da infecção por clostridium difficile.
BR112014007405-4A 2011-09-29 2012-09-28 Composto, mio-inositol-pentaquisfosfato-2-peg(400) e forma farmacêutica BR112014007405B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11007935 2011-09-29
EP11007933.2 2011-09-29
EP11007933 2011-09-29
EP11007935.7 2011-09-29
PCT/EP2012/004088 WO2013045107A1 (en) 2011-09-29 2012-09-28 Pharmaceutical compounds for use in the therapy of clostridium difficile infection

Publications (2)

Publication Number Publication Date
BR112014007405A2 true BR112014007405A2 (pt) 2017-04-04
BR112014007405B1 BR112014007405B1 (pt) 2021-07-13

Family

ID=47022623

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014007405-4A BR112014007405B1 (pt) 2011-09-29 2012-09-28 Composto, mio-inositol-pentaquisfosfato-2-peg(400) e forma farmacêutica

Country Status (14)

Country Link
US (1) US9358243B2 (pt)
EP (2) EP3521294A1 (pt)
JP (1) JP5766884B2 (pt)
CN (2) CN105949234B (pt)
AU (2) AU2012314932B2 (pt)
BR (1) BR112014007405B1 (pt)
CA (1) CA2849426C (pt)
DK (1) DK2773648T3 (pt)
EA (1) EA024069B1 (pt)
ES (1) ES2727633T3 (pt)
IL (1) IL231698A (pt)
MX (1) MX347723B (pt)
PL (1) PL2773648T3 (pt)
WO (1) WO2013045107A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2054044B1 (de) * 2006-08-02 2014-07-23 Johannes Gutenberg-Universität Mainz Arzneimittel gegen lct-vergiftungen
PL3386994T3 (pl) 2015-12-11 2020-05-18 ETH Zürich 4,6-di-(o-tiofosforano)-inozytolo-1,2,3,5-tetra-o-siarczan dla zakażenia c. difficile
US11028112B2 (en) 2015-12-11 2021-06-08 Eth Zurich Inositol derivatives for use in pathological crystallization
EP3848053A1 (en) * 2015-12-11 2021-07-14 Universität Bern Inositol derivatives for use in pathological crystallization
US11707470B2 (en) 2015-12-11 2023-07-25 Eth Zurich Inositol derivatives for use in pathological crystallization
CN106474458B (zh) * 2017-01-05 2020-03-24 重庆医科大学 白介素-27在治疗艰难梭菌感染中的应用
WO2020058321A1 (en) * 2018-09-18 2020-03-26 Inositec Ag Calcium oxalate crystallization inhibitors for renal disorders
KR102651652B1 (ko) 2018-10-11 2024-03-26 사니핏 테라퓨틱스 에스.에이. 이소성 석회화의 치료를 위한 이노시톨 포스페이트
KR20210148078A (ko) 2019-01-30 2021-12-07 사니핏 테라퓨틱스 에스.에이. 조직 관류 증가에 사용하기 위한 이노시톨 포스페이트 화합물
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
US20230167140A1 (en) * 2020-04-30 2023-06-01 Shanghai Senhui Medicine Co., Ltd. Inositol derivative and use thereof
CA3199478A1 (en) 2020-11-20 2022-05-27 Vifor (International) Ag Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
US20240100074A1 (en) 2021-01-26 2024-03-28 Vifor (International) Ag Clinical Dosing Schedule of Inositol Phosphate Oligo(Ethylene Glycol) Compounds
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5444901A (en) * 1977-09-12 1979-04-09 Ricoh Kk Treating liquid for flat printing plate
SE8605063D0 (sv) * 1986-11-26 1986-11-26 Matti Siren Derivatives of cyclohexane
GB8705811D0 (en) * 1987-03-11 1987-04-15 Research Corp Ltd Inositol derivatives
EP2054044B1 (de) * 2006-08-02 2014-07-23 Johannes Gutenberg-Universität Mainz Arzneimittel gegen lct-vergiftungen
DE102006062250A1 (de) * 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
US8809392B2 (en) * 2008-03-28 2014-08-19 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
WO2010049921A1 (en) * 2008-10-31 2010-05-06 Alimentary Health Limited Disaccharides
WO2012138963A1 (en) * 2011-04-06 2012-10-11 The Board Of Regents Of The University Of Texas System Inositol hexakisphosphate analogs and uses thereof

Also Published As

Publication number Publication date
CN103958535A (zh) 2014-07-30
CA2849426C (en) 2020-03-24
AU2017202419B2 (en) 2017-08-31
JP2014532049A (ja) 2014-12-04
AU2017202419A1 (en) 2017-05-11
WO2013045107A1 (en) 2013-04-04
EP3521294A1 (en) 2019-08-07
EP2773648A1 (en) 2014-09-10
US20140235590A1 (en) 2014-08-21
AU2012314932B2 (en) 2017-01-19
CN105949234A (zh) 2016-09-21
DK2773648T3 (da) 2019-05-20
EA024069B1 (ru) 2016-08-31
MX2014003771A (es) 2015-03-20
BR112014007405B1 (pt) 2021-07-13
MX347723B (es) 2017-05-10
EP2773648B1 (en) 2019-03-13
NZ624189A (en) 2015-05-29
IL231698A (en) 2017-06-29
ES2727633T3 (es) 2019-10-17
EA201490726A1 (ru) 2014-08-29
AU2012314932A1 (en) 2014-05-15
CN105949234B (zh) 2018-07-10
US9358243B2 (en) 2016-06-07
CA2849426A1 (en) 2013-04-04
PL2773648T3 (pl) 2020-03-31
JP5766884B2 (ja) 2015-08-19

Similar Documents

Publication Publication Date Title
BR112014007405A2 (pt) composto; forma farmacêutica; e hexasulfato de inositol
NI201200192A (es) Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica.
BR112012018232B8 (pt) Compostos derivados de furo [3,2-b] pirano úteis na síntese de análogos de halicondrina b e métodos de sintetização de er-80402 e de eribulina
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
PE20151423A1 (es) Derivados tetrahidropiranilo inhibidores del hcv
CO7350620A2 (es) Nuevos derivados de piridina
BR112014010407A2 (pt) compostos de azetidina, composições e seu uso como inibidores de hidrolase de epóxido solúvel
BR112013031463A2 (pt) piridina-2-amidas úteis como agonistas de cb2
CR20130543A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
NI201200191A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
CL2015002520A1 (es) Compuestos novedosos de pirimidina y piridina y su uso.
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
BR112015013124A2 (pt) novos derivados de piridina
IN2014CN04530A (pt)
MX2015010354A (es) Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
CO6630184A2 (es) Formulaciones famacéuticas que comprenden derivados de 1 (beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de sglt
SV2009003199A (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BR112012011310A2 (pt) compostos derivados de 8-azabiciclo[3.2.1]octano-8-carboxamida, seu medicamento, seu agente terapêutico e seu uso
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
NI201000134A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
EA201270302A1 (ru) Безводные формы производных пиридина

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/09/2012, OBSERVADAS AS CONDICOES LEGAIS.